Biomaxima (WAR:BMX) Debt-to-Equity : 0.27 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Biomaxima Debt-to-Equity?

Biomaxima's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was zł3.80 Mil. Biomaxima's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was zł9.06 Mil. Biomaxima's Total Stockholders Equity for the quarter that ended in Dec. 2023 was zł46.97 Mil. Biomaxima's debt to equity for the quarter that ended in Dec. 2023 was 0.27.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biomaxima's Debt-to-Equity or its related term are showing as below:

WAR:BMX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 0.32 Max: 0.94
Current: 0.27

During the past 13 years, the highest Debt-to-Equity Ratio of Biomaxima was 0.94. The lowest was 0.11. And the median was 0.32.

WAR:BMX's Debt-to-Equity is ranked worse than
52.33% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs WAR:BMX: 0.27

Biomaxima Debt-to-Equity Historical Data

The historical data trend for Biomaxima's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomaxima Debt-to-Equity Chart

Biomaxima Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.74

0.63

0.59

0.11

0.27

Biomaxima Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.11	0.01	0.14	0.18	0.27

Competitive Comparison of Biomaxima's Debt-to-Equity

For the Diagnostics & Research subindustry, Biomaxima's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomaxima's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biomaxima's Debt-to-Equity falls into.

Biomaxima Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biomaxima's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.797	+	9.064)	/	46.974
	=	0.27

Biomaxima's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.797	+	9.064)	/	46.974
	=	0.27

Biomaxima (WAR:BMX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biomaxima Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biomaxima's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomaxima (WAR:BMX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomaxima SA (WAR:BMX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

944:Germany

Address

5 Vetterow Street, Lublin, POL, 20-277

Website

http://www.biomaxima.com

Biomaxima SA is a Polish company, produces microbiology media as well as a wide range of reagents and in Vitro diagnostics equipment. The company is also a distributor of products of recognized global diagnostics companies such as Nova Biomedical, Mitsubishi Chemical and Biologist. Its products include Systems Antibiotic Susceptibility Testing, Urine Analysis Systems, Hematological Reagents along with Analyzers, ion Selective Analyzers with Reagents, Immunological Analyzer of Cardiac markers with reagents, Glucose Meters and analyzers for Gasometric and Critical Blood Tests.

Biomaxima (WAR:BMX) Headlines

No Headlines